AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Atea Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.39+0.07 (+1.62%)
Close on Oct 19, 2026
- Market cap
- $351.42M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.33 (+43.46%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $351.42M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.72
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$165.29M
- EPS, diluted
- -$2.08
- Book value per share
- $2.55
- Diluted shares
- 80M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$183.61M
Net income
-$165.29M
EPS, diluted
-$2.08
Free cash flow
–
Reported periodTrailing twelve months